Abstract
Background: Early-onset pancreatic cancer (EOPC) represents 5–10% of all pancreatic ductal adenocarcinoma (PDAC) cases, and the etiology of this form is poorly understood. It is not clear if established PDAC risk factors have the same relevance for younger patients. This study aims to identify genetic and non-genetic risk factors specific to EOPC. Methods: A genome-wide association study was performed, analysing 912 EOPC cases and 10 222 controls, divided into discovery and replication phases. Furthermore, the associations between a polygenic risk score (PRS), smoking, alcohol consumption, type 2 diabetes and PDAC risk were also assessed. Results: Six novel SNPs were associated with EOPC risk in the discovery phase, but not in the replication phase. The PRS, smoking, and diabetes affected EOPC risk. The OR comparing current smokers to never-smokers was 2.92 (95% CI 1.69–5.04, P = 1.44 × 10−4). For diabetes, the corresponding OR was 14.95 (95% CI 3.41–65.50, P = 3.58 × 10−4). Conclusion: In conclusion, we did not identify novel genetic variants associated specifically with EOPC, and we found that established PDAC risk variants do not have a strong age-dependent effect. Furthermore, we add to the evidence pointing to the role of smoking and diabetes in EOPC.
Original language | English |
---|---|
Pages (from-to) | 1417-1425 |
Number of pages | 9 |
Journal | Digestive and Liver Disease |
Volume | 55 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 2023 |
Bibliographical note
Funding Information:This study was supported by Fondazione Arpa and Fondazione Tizzi (to Daniele Campa); Inter-COST project no. LTC19015 provided by the Ministry of Education Youth and Sports of the Czech Republic (to Pavel Soucek); the Czech Health Research Council, project no.: NV19-03-00097 (to Beatrice Mohelnikova-Duchonova); the Italian Ministry of Health grants (Ricerca Corrente 2018-2021) to Fondazione “Casa Sollievo della Sofferenza” IRCCS Hospital, San Giovanni Rotondo (FG), Italy and by the “5 × 1000″ voluntary contribution. The EPIC-Oxford study has received funding from Cancer Research UK (C8221/A19170 and C8221/A29017) and the Medical Research Council (MR/M012190/1). The research leading to these results has received funding from AIRC under IG 2021 - ID. 26201 project – P.I. Gabriele Capurso. This article is based upon work from COST Action TRANSPAN, CA21116, supported by COST (European Cooperation in Science and Technology).
Funding Information:
This research used genotyping data provided to the PANDoRA consortium by the EPIC cohort, for which we would like to thank the contributors from EPIC UK and EPIC NL. We are grateful to all the participants who have been part of the project and to Prof. Vermeulen R.C.H. (University of Utrecht) for the EPIC genotyping data. Pavel Vodicka acknowledges projects NU21-07-00247 and Integrative strategy in development of personalized medicine of selected malignant tumours and its impact on quality of life, IMTS: 313011V446, co-financed by the European Regional Development Fund.
Publisher Copyright:
© 2023 Editrice Gastroenterologica Italiana S.r.l.